Literature DB >> 16781728

The role of natural IgM in myocardial ischemia-reperfusion injury.

Ming Zhang1, Lloyd H Michael, Sandrine A Grosjean, Ralph A Kelly, Michael C Carroll, Mark L Entman.   

Abstract

Myocardial ischemia-reperfusion injury represents a combination of factors, namely the intrinsic cellular response to ischemia and the extrinsic acute inflammatory response. Recent studies in mesenteric and skeletal muscle reperfusion models identified natural IgM as a major initiator of pathology through the activation of the complement system and inflammatory cells. To determine whether a similar mechanism is involved in myocardial tissues, mice bearing an altered natural IgM repertoire (Cr2-/-) were examined in a murine model of coronary artery ischemia. Notably, these mice were significantly protected based on the reduced infarct size, limited apoptosis of cardiomyocytes, and decreased neutrophil infiltration. Protection was IgM-dependent as reconstitution of these mice with wild-type IgM restored myocardial reperfusion injury. These results support a model in which natural IgM initiates the acute inflammatory response in the myocardium following ischemia and reperfusion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16781728     DOI: 10.1016/j.yjmcc.2006.02.006

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  39 in total

1.  Asbestos activates CH12.LX B-lymphocytes via macrophage signaling.

Authors:  Devon L Rasmussen; Jean C Pfau
Journal:  J Immunotoxicol       Date:  2011-12-01       Impact factor: 3.000

Review 2.  The role of complement in the early immune response to transplantation.

Authors:  Steven H Sacks; Wuding Zhou
Journal:  Nat Rev Immunol       Date:  2012-05-25       Impact factor: 53.106

Review 3.  How dying cells alert the immune system to danger.

Authors:  Hajime Kono; Kenneth L Rock
Journal:  Nat Rev Immunol       Date:  2008-03-14       Impact factor: 53.106

4.  Modulation of subsets of cardiac B lymphocytes improves cardiac function after acute injury.

Authors:  Luigi Adamo; Lora J Staloch; Cibele Rocha-Resende; Scot J Matkovich; Wenlong Jiang; Geetika Bajpai; Carla J Weinheimer; Attila Kovacs; Joel D Schilling; Philip M Barger; Deepta Bhattacharya; Douglas L Mann
Journal:  JCI Insight       Date:  2018-06-07

5.  Targeting pathogenic postischemic self-recognition by natural IgM to protect against posttransplantation cardiac reperfusion injury.

Authors:  Carl Atkinson; Fei Qiao; Xiaofeng Yang; Peng Zhu; Nicholas Reaves; Liudmila Kulik; Martin Goddard; V Michael Holers; Stephen Tomlinson
Journal:  Circulation       Date:  2015-02-17       Impact factor: 29.690

6.  Early complement factors in the local tissue immunocomplex generated during intestinal ischemia/reperfusion injury.

Authors:  Haekyung Lee; Danielle J Green; Lawrence Lai; Yunfang Joan Hou; Jens C Jensenius; David Liu; Cheolho Cheong; Chae Gyu Park; Ming Zhang
Journal:  Mol Immunol       Date:  2009-12-09       Impact factor: 4.407

7.  Human natural IgM can induce ischemia/reperfusion injury in a murine intestinal model.

Authors:  Ming Zhang; Elisabeth M Alicot; Michael C Carroll
Journal:  Mol Immunol       Date:  2008-07-30       Impact factor: 4.407

Review 8.  The importance of non-HLA antibodies in transplantation.

Authors:  Qiuheng Zhang; Elaine F Reed
Journal:  Nat Rev Nephrol       Date:  2016-06-27       Impact factor: 28.314

9.  Pathogenic natural antibodies recognizing annexin IV are required to develop intestinal ischemia-reperfusion injury.

Authors:  Liudmila Kulik; Sherry D Fleming; Chantal Moratz; Jason W Reuter; Aleksey Novikov; Kuan Chen; Kathy A Andrews; Adam Markaryan; Richard J Quigg; Gregg J Silverman; George C Tsokos; V Michael Holers
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

Review 10.  Post-infarct remodelling: contribution of wound healing and inflammation.

Authors:  Stefan Frantz; Johann Bauersachs; Georg Ertl
Journal:  Cardiovasc Res       Date:  2008-10-31       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.